Human ovarian cancer cells and tissues were examined for the presence or absence of a 42-bp splicing variant of ERCC1 gene, and for a possible functional role of this 42-bp sequence. This speci®c sequence exists in exon I, the 5'-UTR of the gene. Loss of this 42-bp sequence was associated with increased ERCC1 mRNA expression, in an assessment of 121 ovarian cancer specimens (p2510
76
). In cells in tissue culture, the absence of the 42-bp segment was associated with a twofold increased ability to drive transcription in a Luciferase reporter system. Protein can be demonstrated in ovarian cancer cells based on EMSA analysis. Computer analysis shows that this 42-bp sequence contains several binding sites, including a core-binding domain for protein RFX1, transcriptional repressor. These preliminary results lay the groundwork in determination of potential roles for a negative regulatory element in NER repair pathway. Oncogene (2001) 20, 7694 ± 7698.
Keywords: ERCC1; nucleotide excision repair; ovarian cancer; transcriptional factor Nucleotide excision repair (NER) is the pathway that repairs bulky covalent damage to cellular DNA (Sancar, 1994; Van Duin et al., 1986) . Excision repair cross complementation group-1 (ERCC1) gene is a critical NER component and participates in several functions, including DNA damage recognition and DNA strand incision (Van Vuuren et al., 1995; Mu et al., 1996; Reed 1998) . Inhibition of ERCC1 expression by antisense and pharmaceutical approaches has been reported to reduce cisplatin-DNA adduct repair (Yang et al., 2000; Bonovich et al., 2000) . NER is important in the development of cellular and clinical resistance to platinum-based anticancer agents (Parker et al., 1991; Li et al., 1998) . Observations have been reported for human ovarian cancer and gastric cancer that ERCC1 expression in tumor tissue is related to clinical resistance to platinum-based chemotherapy (Dabholkar et al., 1994; Metzger et al., 1998) . With the focus on the question of a possible in¯uence on ERCC1 expression, we analysed 5'-UTR regions of the ERCC1 mRNA that includes untranslated exon 1. Oncogene (2001) 20, 7694 ± 7698 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Figure 1 Relative level of mRNA expression of ERCC1 in a total of 121 human ovarian cancer specimens measured by RT ± PCR. One hundred and twenty-one fresh tumor specimens were obtained from advanced ovarian cancer patients and¯ash frozen at 7808C until RNA/DNA extraction. Total RNAs were extracted by hot phenol chloroform method (Palmiter et al., 1974) . Through Reverse Transcription SuperScript Preampli®ca-tion System, cDNAs were generated from 5 mg of total RNA per sample (Life Technologies, Inc). Oligonucleotide primers for ERCC1 and for b-Actin (randomly selected exon-primers) were synthesized by Lofstrand Labs Limited (Gaithersburg, MD, USA). In both ampli®cation experiments, PCR was performed with cDNAs at 35 cycles and using AmpliTaq DNA polymerase (Perkin Elmer Cetus, Norwalk, CT, USA). Aliquots of ampli®ed DNAs were electrophoresed through a 1.5% agarose gel, and transferred to Hybond N+membranes (Amersham, UK) for Southern hybridization analysis. Hybridization was performed with¯uorescent-11-dUTP labeled oligonucleotide probes (synthesized by Lofstrand Labs Limited) for ERCC1 and for û-Actin, via the terminal transferase reaction. Probes were hybridized to their ampli®ed DNAs at 428C overnight (ECL 3'-oligolabelling and detection systems, Amersham Life Science). Densitometric data were conducted by using Collage Image Analysis Program (Fotodyne Inc., New Berlin, WI, USA) PCR ampli®ed DNAs of ERCC1 exon I ± II from 121 ovarian cancer specimens were separated by gel-electrophoresis and puri®ed with Qiaex II gel extraction kit (Qiagen Inc). The DNA fragments were used in a¯uorescence-based cycle sequencing reaction. PCR primers in ERCC1 expression experiments were used in the sequencing analyses. 100 ng of PCR DNAs from ovarian cancer specimens were applied as sequence templates. ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit, with AmpliTaq DNA Polymerase, FS, were utilized for the sequencing reaction on the GeneAmp PCR System 9600 Thermal Cycler (PE Applied Biosystems, Foster City, CA, USA). Puri®cation of the extension products was performed by ethanol precipitation method (manufacturer protocol). Samples were resuspended in loading buer (deionized formamide:25 mM EDTA with blue dextran=5 : 1) and denatured by heating at 958C for 2 min. Two ml of denatured samples were loaded into each lane and electrophoresed in 16TBE buer for 7 h on the ABI prism 377 DNA sequencer (PE Applied Biosystems) We ®rst assessed relative mRNA levels of ERCC1 in a series of 121 specimens obtained from CHTN, Columbus, Ohio, USA. RT ± PCR was performed with randomly selected primers of b-Actin; and ERCC1 to amplify a fragment containing exons 3 ± 5 in these samples. ERCC1 relative mRNA expression was corrected for its b-Actin value. The value of an internal control H9, human lymphocyte cells was given the value of 1.0, for purposes of comparative studies of the ovarian cancer samples. Therefore, we assigned patient samples to two groups based on ERCC1 value: ERCC1 relative-low (51) and ERCC1 relative-high (41). In the total of 121 ovarian cancer samples, 27% of patients (33 of 121) had relative expression levels that exceeded the value of 1.0 (relative-high) and 73% (88 of 121) had levels below 1.0 (relative-low) (Figure 1) .
To examine the potential role of the 5'-UTR in ERCC1 mRNA expression, we performed RT ± PCR with speci®c primers targeting the 5'-UTR region to amplify a fragment containing exon I (UTR) and exon II (containing the initiation codon) of the ERCC1 gene in the 121 samples. The cDNA amplimers for ERCC1 were separated by agarose gel electrophoresis and stained with ethidium bromide (Figure 2 : top a and b). Corresponding b-Actin results from Southern hybridization are also shown in Figure 2 (bottom a and b) . Two PCR-amplimers from the same sample for the target segment within the UTR region appeared in some samples. Comparing top panels a and b ( Figure  2 ), a prevalence of the 2-amplimers occurred in the high expression group (top b) while appearing less frequently in the low expression group (top a). Of those patients who showed a single amplimer, only three of 59 (5.1%) specimens showed ERCC1 mRNA levels 41.0. Of patients who showed two amplimers for this region, 30 of 62 (48.4%) specimens had ERCC1 levels 41.0. The dierence between these two groups is statistically signi®cant: two-sided P510 76 by Fischer's exact test (Table 1) . Taken together, these results suggest a correlation between high ERCC1 Figure 4 (a) Plasmid DNA constructions. The constructions of pGL3/ERCC1 for the transient transfection were initially constructed using PCR ampli®cation of the ERCC1 cDNA. The construct I, 219-bp fragment (without the 42-bp sequence) and the full construct II, 261-bp fragment (containing the 42-bp sequence) from the ERCC1 gene were ®rst inserted into pBlue-TOPO reporter vector (Invitrogen Inc., Carlsbad, CA, USA) to obtain two necessary restriction sites. The presence of compatible restriction sites of Kpn1 and HindIII in both pBlue-TOPO vector and pGL3 basic luciferase reporter vector (Promega Inc., Madison, WI, USA) made it possible to include the fragments (+/7) 42-bp in the ®nal constructs of pGL3/ERCC1. After digestion of pBlue-TOPO/ERCC1 and pGL3 vector with Kpn1 and HindIII, puri®ed fragments with (+/7) 42-bp from pBlue-TOPO/ERCC1 were ligated into pGL3 vector. DNA sequencing analysis determined con®rmation of the correct sequence of each plasmid construct. (b) Cell culture and transient transfection assays. Human ovarian cancer A2780 and A2780/CP70 cells were grown in RPMI 1640 medium supplemented with 10% FBS, 1% glucose, 1% penicillin and streptomycin. The cells were maintained at 378C and 5% CO 2 in a humidi®ed incubator and were passaged weekly. 3610 5 cells per well were seeded into 6-well tissue culture plates the day before transfection for luciferase assay. A non-liposomal formulation FuGENE-6 transfection system (Boehringer Mannheim) was used to transfect the reporter construct (pGL3/ERCC1) into the two cell lines. According to the manufacturer's procedure, 6 ml of FuGENE-6 was mixed with 94 ml of serum-free RPMI 1640 medium and left for 5 min at R-T. This mix was added to 2 mg of plasmids and incubated for 15 min at R-T. The 100 ml FuGENE-DNA/medium mixture was added dropwise to cells in each well of the plates without removing the medium from the cells. The cells were incubated for 24 h and extracted by adding 300 ml 16CCLR lysis buer (Luciferase Assay System, Promega) per well for 10 min at R-T. The lysates were collected in the supernatant by scraping and centrifugation. The pGL3-control vector and the pGL3-basic vector were used as positive and negative controls, respectively. Chemiluminescence was measured in a Luminometer ML 3000 (DYNEX Tech, VA, USA) by mixing 20 ml cell extract and 100 ml luciferase assay reagent. Fire¯y luciferase activities were normalized to renilla luciferase activity. All assays were done in duplicate and at least two times expression and the existence of a second form of ERCC1 mRNA.
Direct DNA sequencing of the cDNA from each of the 121 ovarian cancer tumor specimens, for the exon I and exon II segment of ERCC1 from bp +1 to bp +261 con®rmed that specimens with two amplimers for this segment contained two distinct sequences. The longer sequences included the complete target sequence, 261-bp (WT), and the shorter sequences that demonstrated a 42-bp deletion between nucleotides 94 to 135 of exon 1 (Figure 3: panel b) . Ampli®ed genomic DNA targeting the same region of ERCC1 from individuals who showed two distinct sequences of the cDNA, demonstrated only one amplimer, the expected full-length sequence (261-bp) (data not shown), suggesting that the shorter sequences observed in these specimens were no due to a genetic defect in individual patients for ERCC1. This also indicates that the deletion occurred during post-transcription.
In order to determine the potential function of the 42-bp DNA segment in ERCC1 expression, Exon 1 constructs were analysed for their ability to promote expression of a promoter-less Luciferase-containing plasmid. Two reporter constructs, one containing the ®rst 261-bp of exons I, II, and part of III of the gene, were inserted into the pGL-3 vector with a luciferase reporter. The second construct was similar to the 261-bp segment, but shortened by the appropriate 42-bp deletion from nucleotide 94 to 135 (Figure 4a ). When the two plasmids were transiently transfected into two human ovarian cancer cell lines, A2780 (cisplatinsensitive) and A2780/CP70 (cisplatin-resistant) (Behrens et al., 1987) , the construct that lacked the 42-bp sequence was associated with a twofold increase in luciferase production compared to the full-length construct (Figure 4b ). Therefore, in both cell lines, the absence of the 42-bp sequence was associated with increased Luciferase expression. These results would suggest that this UTR 42-bp sequence has a role in the suppression of ERCC1 when expressed in ovarian cancer cells, regardless of the cells sensitivity or resistance to platinum-chemotherapy.
Nuclear extracts from A2780 and A2780/CP70 cells provided a shift in a 32 P-labeled 42-bp oligo ( Figure 5 ). The shifted band present in both cell line extracts was consistent with the presence of an intracellular protein that recognizes this speci®c 42-bp sequence. Database program, MatInspector V2.2, was used to assess possible binding sites for transcriptional modulators (Quandt et al., 1995) , within the 42-bp sequence in question. Potential binding sites were identi®ed for three proteins, including RFX1, AP4 and CETS1P54. Of these proteins, RFX1 has been reported to have potential transcriptional repressor activity. The core consensus binding site for RFX1 resides in the middle of this 42-bp sequence, as shown in (Figure 3a) .
In summary, the current data suggest that a 42-bp deletion of the ERCC1 5'-UTR may be associated with high mRNA level of ERCC1 in human ovarian cancer tissues. Intracellular protein is present in human ovarian cancer cell lines that recognizes this 42-bp Figure 5 Electrophoretic Mobility Shift Assay (EMSA). Nuclear extracts were prepared from the two cell lines A2780 and A2780/ CP70 according to the procedure described by Digman et al., 1983 . The cell pellets were resuspended in 1.5 volumes of lysis buer [70 mM KCl, 1.5 mM MgCl 2 , 0.5 mM sodium orthovanadate, 0.4 mM sodium¯uoride (NaF), 0.5 mM phenylmethylsulfonyl¯uoride (PMSF), 1.0 mM dithiothreitol (DTT), 25 mM HEPES]. The mixture was incubated on ice for 20 min and the cells were lysed by the addition of 1.6 volumes of extraction buer [0.5 mM EDTA, 20% glycerol, 1.66 M KCl, 0.4 mM NaF, 0.4 mM sodium orthovanadate, 0.1 mM PMSF, 1.0 mM 1,1,1,-trichloro-2,2-bis(p-chlorophenyl)ethane (DDT), 25 mM HEPES], with constant shaking at 48C for 4 h. Samples were centrifuged at 55 0006g for 1 h at 48C to pellet the debris. The supernatant containing the nuclear extract was dialyzed at 48C for 4 h against the dialysis buer [20 mM HEPES, 50 mM KCl, 0.1 mM EDTA, 10% glycerol, 0.4 mM NaF, 0.4 mM sodium orthovanadate, 0.1 mM PMSF, 1.0 mM DTT]. Protein concentrations of the nuclear extracts were determined by BCA Protein Assay (Pierce). A 42-bp double-stranded DNA oligonucleotide corresponding to nucleotides 94 to 135 of ERCC1 gene was used as probe and was end-labeled with [g-32 P]ATP using T4 kinase and puri®ed with Mini Quick Spin Oligo Columns (Boehringer Mannheim). DNAprotein binding reactions were performed by incubation of 10 mg of nuclear extracts in gel shift binding buer consisting of 25 mM Tris (pH8.0), 10% glycerol, 50 mM KCl, 0.5 mM EDTA, 6.25 mM MgCl 2 , and incubated at RT for 10 min. 1 ml (100 000 c.p.m) of 32 P-labeled oligos were then added to each reaction. The reactions were incubated for 5 min. on ice. After the binding reactions, 1 ml of 106gel loading buer was added to each sample. Nuclear extract-DNA complexes were resolved in 5% non-denaturing PAGE gel using 0.56TBE buer for 5 h. EMSA signals were obtained by exposing of Kodak ®lm to the dried-gel for optimal hours sequence, as demonstrated by EMSA. The existence of a consensus binding site for a known transcriptional repressor, RFX1, suggests that this protein might contribute to the reduced expression of ERCC1 under certain circumstances. Plasmid containing the 42-bp sequence of the ERCC1 5'-UTR appears to reduce the transcription of a luciferase reporter construct and further to increase the potential role of this transcription repressor in ERCC1 expression in human ovarian cancer cell lines. Collectively, the data suggest that the role of this 42-bp sequence is to have a negative transcriptional regulatory in¯uence; possibly mediated through RFX1 or other unknown factors. Understanding the negative regulation of ERCC1 and other NER genes, may lead to a more speci®c approach toward the control of NER.
